Welcome to MutualFunds.com. Please help us personalize your experience.

Select the one that best describes you

Your personalized experience is almost ready.

Join other Individual Investors receiving FREE personalized market updates and research. Join other Institutional Investors receiving FREE personalized market updates and research. Join other Financial Advisors receiving FREE personalized market updates and research.

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission, we hope you enjoy your experience

Channels

Screener

Funds

Advisors

Advisor Access

News

What Johnson & Johnson's Earnings Mean For Mutual Fund Investors (JNJ)

Shauna O'Brien Apr 14, 2015

Before the opening bell on Tuesday, Johnson & Johnson (JNJ) released its first quarter financial results. Here’s what the results mean for mutual fund investors.

Inside JNJ’s Results

Earnings

The company reported earnings of $4.32 billion, or $1.53 per share, down from $4.73 billion, or $1.64 per share, last year. Excluding special items, earnings were $1.56 per share – above analysts’ view of $1.54.

Revenue
Revenue declined 4.1% to $17.37 billion from $18.12 billion last year. Analysts expected to see revenue of $17.31 billion.

Outlook
Looking ahead, JNJ now expects to see FY2015 EPS between $6.04 and $6.19. Previously, the company expected to see EPS between $6.12 and $6.27 per share. Analysts expect to see EPS of $6.16.

JNJ To Seek Acquisitions

The company has a large cash stockpile which it may plan to use for future acquisitions to grow more profitable businesses. Last month, JNJ failed to acquire Pharmacyclics, but there could be more deals in the pipeline.

Mutual Funds to Watch

Investors interested in JNJ may be interested in the funds listed below. These funds currently have the largest stakes in the company.

Symbol	Mutual Fund	Stake
VTSMX	Vanguard Total Stock Market	1.75%
VFINX	Vanguard 500 Index	1.12%
FCNTX	Fidelity® Contrafund®	0.60%

The Bottom Line

The funds listed above allow investors to gain exposure to JNJ while remaining diversified. Investors interested in JNJ may also be interested in Pfizer (PFE) and Merck (MRK).